

S Moein Moghimi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7581674/publications.pdf>

Version: 2024-02-01

228
papers

20,024
citations

15880

67
h-index

12638

137
g-index

237
all docs

237
docs citations

237
times ranked

24092
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell medium-dependent dynamic modulation of size and structural transformations of binary phospholipid/1%-3 fatty acid liquid crystalline nano-self-assemblies: Implications in interpretation of cell uptake studies. <i>Journal of Colloid and Interface Science</i> , 2022, 606, 464-479.	5.0	8
2	Use of "nano"™ prefix is no small matter. <i>Nature</i> , 2022, , .	13.7	1
3	Critical issues and pitfalls in serum and plasma handling for complement analysis in nanomedicine and bionanotechnology. <i>Nano Today</i> , 2022, 44, 101479.	6.2	10
4	Pro-inflammatory concerns with lipid nanoparticles. <i>Molecular Therapy</i> , 2022, 30, 2109-2110.	3.7	16
5	Antibody-Dependent Complement Responses toward SARS-CoV-2 Receptor-Binding Domain Immobilized on "Pseudovirus-like" Nanoparticles. <i>ACS Nano</i> , 2022, , .	7.3	7
6	A structurally diverse library of glycerol monooleate/oleic acid non-lamellar liquid crystalline nanodispersions stabilized with nonionic methoxypoly(ethylene glycol) (mPEG)-lipids showing variable complement activation properties. <i>Journal of Colloid and Interface Science</i> , 2021, 582, 906-917.	5.0	21
7	Editorial: Immune Mechanisms in the Pathologic Response to Particles, Fibers, and Nanomaterials. <i>Frontiers in Immunology</i> , 2021, 12, 665810.	2.2	0
8	Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines. <i>Molecular Therapy</i> , 2021, 29, 898-900.	3.7	91
9	Integrin-Targeted, Short Interfering RNA Nanocomplexes for Neuroblastoma Tumor-Specific Delivery Achieve <i>MYCN</i> Silencing with Improved Survival. <i>Advanced Functional Materials</i> , 2021, 31, 2104843.	7.8	12
10	Dendrimer end-terminal motif-dependent evasion of human complement and complement activation through IgM hitchhiking. <i>Nature Communications</i> , 2021, 12, 4858.	5.8	14
11	Microneedle-based devices for point-of-care infectious disease diagnostics. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2344-2361.	5.7	35
12	Complement opsonization of nanoparticles: Differences between humans and preclinical species. <i>Journal of Controlled Release</i> , 2021, 338, 548-556.	4.8	20
13	Roadmap on nanomedicine. <i>Nanotechnology</i> , 2021, 32, 012001.	1.3	17
14	Non-Lamellar Liquid Crystalline Nanocarriers for Thymoquinone Encapsulation. <i>Molecules</i> , 2020, 25, 16.	1.7	30
15	Airborne Particulate Matter and SARS-CoV-2 Partnership: Virus Hitchhiking, Stabilization and Immune Cell Targeting " A Hypothesis. <i>Frontiers in Immunology</i> , 2020, 11, 579352.	2.2	16
16	The Journal of Nanotheranostics: A New Open-Access Journal at the Interface of Nanotechnology, Materials Science, and Medicine for Precision Medicine. <i>Journal of Nanotheranostics</i> , 2020, 1, 56-57.	1.7	0
17	Complement activation by drug carriers and particulate pharmaceuticals: Principles, challenges and opportunities. <i>Advanced Drug Delivery Reviews</i> , 2020, 157, 83-95.	6.6	39
18	A rally for brain targeting: the advent of a new era. <i>Therapeutic Delivery</i> , 2020, 11, 465-470.	1.2	3

#	ARTICLE	IF	CITATIONS
19	Hexosome engineering for targeting of regional lymph nodes. <i>Materialia</i> , 2020, 11, 100705.	1.3	17
20	Tuning the Engines of Nanomedicine. <i>Molecular Therapy</i> , 2020, 28, 693-694.	3.7	4
21	Overcoming Nanoparticle-Mediated Complement Activation by Surface PEG Pairing. <i>Nano Letters</i> , 2020, 20, 4312-4321.	4.5	70
22	Complement Activation by Nanomaterials. <i>Molecular and Integrative Toxicology</i> , 2020, , 83-98.	0.5	3
23	Elevated circulating endothelin-1 as a potential biomarker for high-risk COVID-19 severity. <i>Precision Nanomedicine</i> , 2020, 3, .	0.4	8
24	The diagnostic potential of microneedles in infectious diseases. <i>Precision Nanomedicine</i> , 2020, 3, .	0.4	2
25	Reprogramming the lymphocyte axis for advanced immunotherapy. <i>Advanced Drug Delivery Reviews</i> , 2019, 141, 1-2.	6.6	0
26	Perturbation of mitochondrial bioenergetics by polycations counteracts resistance to BRAFE600 inhibition in melanoma cells. <i>Journal of Controlled Release</i> , 2019, 309, 158-172.	4.8	3
27	On the issue of transparency and reproducibility in nanomedicine. <i>Nature Nanotechnology</i> , 2019, 14, 629-635.	15.6	149
28	Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide. <i>Nature Communications</i> , 2019, 10, 4635.	5.8	98
29	CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs. <i>Advanced Drug Delivery Reviews</i> , 2019, 141, 41-46.	6.6	29
30	Determination of Polycation-Mediated Perturbation of Mitochondrial Respiration in Intact Cells by High-Resolution Respirometry (Oxygraph-2k, OROBOROS). <i>Methods in Molecular Biology</i> , 2019, 1943, 313-322.	0.4	8
31	Lactate Dehydrogenase Assay for Assessment of Polycation Cytotoxicity. <i>Methods in Molecular Biology</i> , 2019, 1943, 291-299.	0.4	21
32	Combined Fluorimetric Caspase-3/7 Assay and Bradford Protein Determination for Assessment of Polycation-Mediated Cytotoxicity. <i>Methods in Molecular Biology</i> , 2019, 1943, 301-311.	0.4	0
33	Complement therapeutics meets nanomedicine: overcoming human complement activation and leukocyte uptake of nanomedicines with soluble domains of CD55. <i>Journal of Controlled Release</i> , 2019, 302, 181-189.	4.8	24
34	The Interplay Between Blood Proteins, Complement, and Macrophages on Nanomedicine Performance and Responses. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 581-592.	1.3	47
35	Pharmacokinetic analysis reveals limitations and opportunities for nanomedicine targeting of endothelial and extravascular compartments of tumours. <i>Journal of Drug Targeting</i> , 2019, 27, 690-698.	2.1	15
36	Immunoglobulin deposition on biomolecule corona determines complement opsonization efficiency of preclinical and clinical nanoparticles. <i>Nature Nanotechnology</i> , 2019, 14, 260-268.	15.6	204

#	ARTICLE	IF	CITATIONS
37	Targeting Biological Barriers: Turning a Wall into a Therapeutic Springboard. <i>Molecular Therapy</i> , 2018, 26, 933-934.	3.7	7
38	Nanomedicine safety in preclinical and clinical development: focus on idiosyncratic injection/infusion reactions. <i>Drug Discovery Today</i> , 2018, 23, 1034-1042.	3.2	58
39	Translational gaps in animal models of human infusion reactions to nanomedicines. <i>Nanomedicine</i> , 2018, 13, 973-975.	1.7	23
40	Cisplatin Encapsulation Generates Morphologically Different Multicompartment in the Internal Nanostructures of Nonlamellar Liquid-Crystalline Self-Assemblies. <i>Langmuir</i> , 2018, 34, 6570-6581.	1.6	33
41	Multivalent targeting and killing of HER2 overexpressing breast carcinoma cells with methotrexate-encapsulated tetra-specific non-overlapping variable domain heavy chain anti-HER2 antibody-PEG-liposomes: In vitro proof-of-concept. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 122, 42-50.	1.9	23
42	Nanoparticle transport pathways into tumors. <i>Journal of Nanoparticle Research</i> , 2018, 20, 169.	0.8	50
43	C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes. <i>ACS Nano</i> , 2018, 12, 5834-5847.	7.3	86
44	Skin Biosensing and Bioanalysis: what the Future Holds. <i>Precision Nanomedicine</i> , 2018, 1, 124-127.	0.4	3
45	Smart polymers in drug delivery: a biological perspective. <i>Polymer Chemistry</i> , 2017, 8, 41-51.	1.9	55
46	Peptide and nucleic acid-directed self-assembly of cationic nanovehicles through giant unilamellar vesicle modification: Targetable nanocomplexes for in vivo nucleic acid delivery. <i>Acta Biomaterialia</i> , 2017, 51, 351-362.	4.1	28
47	Polyplex Evolution: Understanding Biology, Optimizing Performance. <i>Molecular Therapy</i> , 2017, 25, 1476-1490.	3.7	146
48	Bypassing adverse injection reactions to nanoparticles through shape modification and attachment to erythrocytes. <i>Nature Nanotechnology</i> , 2017, 12, 589-594.	15.6	154
49	Complement activation turnover on surfaces of nanoparticles. <i>Nano Today</i> , 2017, 15, 8-10.	6.2	67
50	Nanoparticle Technology: Having Impact, but Needing Further Optimization. <i>Molecular Therapy</i> , 2017, 25, 1461-1463.	3.7	4
51	Poly-(amidoamine) dendrimers with a precisely core positioned sulforhodamine B molecule for comparative biological tracing and profiling. <i>Journal of Controlled Release</i> , 2017, 246, 88-97.	4.8	18
52	Complement proteins bind to nanoparticle protein corona and undergo dynamic exchange in vivo. <i>Nature Nanotechnology</i> , 2017, 12, 387-393.	15.6	411
53	Revealing Dynamics of Accumulation of Systemically Injected Liposomes in the Skin by Intravital Microscopy. <i>ACS Nano</i> , 2017, 11, 11584-11593.	7.3	21
54	Interaction of extremophilic archaeal viruses with human and mouse complement system and viral biodistribution in mice. <i>Molecular Immunology</i> , 2017, 90, 273-279.	1.0	5

#	ARTICLE	IF	CITATIONS
55	Nanoparticles and innate immunity: new perspectives on host defence. <i>Seminars in Immunology</i> , 2017, 34, 33-51.	2.7	244
56	ImmunoPEGliposome-mediated reduction of blood and brain amyloid levels in a mouse model of Alzheimer's disease is restricted to aged animals. <i>Biomaterials</i> , 2017, 112, 141-152.	5.7	32
57	In Vitro and In Vivo Differences in Murine Third Complement Component (C3) Opsonization and Macrophage/Leukocyte Responses to Antibody-Functionalized Iron Oxide Nanoworms. <i>Frontiers in Immunology</i> , 2017, 8, 151.	2.2	40
58	Theranostics. , 2017, , 4505-4507.		1
59	Editorial: Interaction Between the Immune System and Nanomaterials: Safety and Medical Exploitation. <i>Current Bionanotechnology</i> , 2016, 2, 3-5.	0.6	5
60	Activation of Human Complement System by Dextran-Coated Iron Oxide Nanoparticles Is Not Affected by Dextran/Fe Ratio, Hydroxyl Modifications, and Crosslinking. <i>Frontiers in Immunology</i> , 2016, 7, 418.	2.2	43
61	Nanoparticle patterning for biomedicine. <i>BiolImpacts</i> , 2016, 6, 183-185.	0.7	3
62	Recognition of extremophilic archaeal viruses by eukaryotic cells: a promising nanoplatform from the third domain of life. <i>Scientific Reports</i> , 2016, 6, 37966.	1.6	5
63	Call for papers: Nanoparticle Development and Applications in Cellular and Molecular Therapies. <i>Molecular Therapy</i> , 2016, 24, 1334-1335.	3.7	3
64	A structurally diverse library of safe-by-design citrem-phospholipid lamellar and non-lamellar liquid crystalline nano-assemblies. <i>Journal of Controlled Release</i> , 2016, 239, 1-9.	4.8	76
65	AFM visualization of sub-50 nm polyplex disposition to the nuclear pore complex without compromising the integrity of the nuclear envelope. <i>Journal of Controlled Release</i> , 2016, 244, 24-29.	4.8	16
66	The Art of Complement: Complement Sensing of Nanoparticles and Consequences. <i>Advances in Delivery Science and Technology</i> , 2016, , 43-51.	0.4	3
67	Soluble and immobilized graphene oxide activates complement system differently dependent on surface oxidation state. <i>Biomaterials</i> , 2016, 78, 20-26.	5.7	35
68	Complement Propriety and Conspiracy in Nanomedicine: Perspective and a Hypothesis. <i>Nucleic Acid Therapeutics</i> , 2016, 26, 67-72.	2.0	15
69	An integrated assessment of morphology, size, and complement activation of the PEGylated liposomal doxorubicin products Doxil [®] , Caelyx [®] , DOXOrubicin, and SinaDoxosome. <i>Journal of Controlled Release</i> , 2016, 221, 1-8.	4.8	152
70	Platelet mimicry: The emperor's new clothes?. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 245-248.	1.7	19
71	Liposomes. , 2016, , 1802-1808.		0
72	Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness. <i>Journal of Extracellular Vesicles</i> , 2015, 4, 29685.	5.5	86

#	ARTICLE	IF	CITATIONS
73	Insidious pathogen-mimicking properties of nanoparticles in triggering the lectin pathway of the complement system. <i>European Journal of Nanomedicine</i> , 2015, 7, .	0.6	6
74	Modulatory Effect of Human Plasma on the Internal Nanostructure and Size Characteristics of Liquid-Crystalline Nanocarriers. <i>Langmuir</i> , 2015, 31, 5042-5049.	1.6	59
75	Cubosomes and hexosomes as versatile platforms for drug delivery. <i>Therapeutic Delivery</i> , 2015, 6, 1347-1364.	1.2	130
76	Polyethylenimine architecture-dependent metabolic imprints and perturbation of cellular redox homeostasis. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2015, 1847, 328-342.	0.5	28
77	Dendrimers in Medicine: Therapeutic Concepts and Pharmaceutical Challenges. <i>Bioconjugate Chemistry</i> , 2015, 26, 1198-1211.	1.8	193
78	Differential Modulation of Cellular Bioenergetics by Poly(L-lysine)s of Different Molecular Weights. <i>Biomacromolecules</i> , 2015, 16, 2119-2126.	2.6	24
79	New platforms for multi-functional ocular lenses: engineering double-sided functionalized nano-coatings. <i>Journal of Drug Targeting</i> , 2015, 23, 305-310.	2.1	16
80	Citrem modulates internal nanostructure of glyceryl monooleate dispersions and bypasses complement activation: Towards development of safe tunable intravenous lipid nanocarriers. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1909-1914.	1.7	64
81	Modulatory Role of Surface Coating of Superparamagnetic Iron Oxide Nanoworms in Complement Opsonization and Leukocyte Uptake. <i>ACS Nano</i> , 2015, 9, 10758-10768.	7.3	82
82	Repeated intraperitoneal injections of liposomes containing phosphatidic acid and cardiolipin reduce amyloid- β^2 levels in APP/PS1 transgenic mice. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 421-430.	1.7	68
83	Recent Advances in Cryo-TEM Imaging of Soft Lipid Nanoparticles. <i>AIMS Biophysics</i> , 2015, 2, 116-130.	0.3	45
84	Polycation-Mediated Integrated Cell Death Processes. <i>Advances in Genetics</i> , 2014, 88, 353-398.	0.8	21
85	Poly(β -hydroxybutyrate-co- β -hydroxyhexanoate) Nanoparticles with Polyethylenimine Coat as Simple, Safe, and Versatile Vehicles for Cell Targeting: Population Characteristics, Cell Uptake, and Intracellular Trafficking. <i>Advanced Healthcare Materials</i> , 2014, 3, 817-824.	3.9	41
86	Mechanisms of complement activation by dextran-coated superparamagnetic iron oxide (SPIO) nanoworms in mouse versus human serum. <i>Particle and Fibre Toxicology</i> , 2014, 11, 64.	2.8	79
87	Cancer nanomedicine and the complement system activation paradigm: Anaphylaxis and tumour growth. <i>Journal of Controlled Release</i> , 2014, 190, 556-562.	4.8	82
88	Nanoparticles in Medicine. , 2014, , 77-89.		5
89	T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: Towards tumor-directed oligoclonal T cell therapy. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2014, 1840, 378-386.	1.1	72
90	Live-cell fluorescent microscopy platforms for real-time monitoring of polyplex-cell interaction: Basic guidelines. <i>Methods</i> , 2014, 68, 300-307.	1.9	10

#	ARTICLE	IF	CITATIONS
91	Just so stories: The random acts of anti-cancer nanomedicine performance. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2014, 10, 1661-1666.	1.7	69
92	The Role of Complement in Antibody Therapy for Infectious Diseases. <i>Microbiology Spectrum</i> , 2014, 2, .	1.2	8
93	Anatomical and Physicochemical Factors Controlling Nanoparticle Pharmacokinetics. <i>Frontiers in Nanobiomedical Research</i> , 2014, , 31-44.	0.1	1
94	Theranostics. , 2014, , 1-3.		2
95	Uptake and Intracellular Trafficking of Nanocarriers. <i>Fundamental Biomedical Technologies</i> , 2014, , 117-138.	0.2	2
96	Reciprocity in the Developmental Regulation of Aquaporins 1, 3 and 5 during Pregnancy and Lactation in the Rat. <i>PLoS ONE</i> , 2014, 9, e106809.	1.1	12
97	Defining and characterizing non-biological complex drugs (NBCDs) – Is size enough? The case for liposomal doxorubicin generics (–liposomal nanosimilars–™) for injection. <i>CaBI Journal</i> , 2014, 3, 56-57.	0.4	5
98	High resolution respirometry analysis of polyethylenimine-mediated mitochondrial energy crisis and cellular stress: Mitochondrial proton leak and inhibition of the electron transport system. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2013, 1827, 1213-1225.	0.5	63
99	Nanomedicine and the complement paradigm. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 458-460.	1.7	68
100	Complement monitoring of Pluronic 127 gel and micelles: Suppression of copolymer-mediated complement activation by elevated serum levels of HDL, LDL, and apolipoproteins AI and B-100. <i>Journal of Controlled Release</i> , 2013, 170, 167-174.	4.8	43
101	Surfactant-mediated complement activation in beagle dogs. <i>International Immunopharmacology</i> , 2013, 17, 33-34.	1.7	7
102	Lactate Dehydrogenase Assay for Assessment of Polycation Cytotoxicity. <i>Methods in Molecular Biology</i> , 2013, 948, 13-22.	0.4	42
103	Structural profiling and biological performance of phospholipid–hyaluronan functionalized single-walled carbon nanotubes. <i>Journal of Controlled Release</i> , 2013, 170, 295-305.	4.8	26
104	Single-Walled Carbon Nanotube Surface Control of Complement Recognition and Activation. <i>ACS Nano</i> , 2013, 7, 1108-1119.	7.3	110
105	Complement activation by PEG-functionalized multi-walled carbon nanotubes is independent of PEG molecular mass and surface density. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2013, 9, 469-473.	1.7	38
106	Genetically engineered T cells bearing chimeric nanoconstructed receptors harboring TAG-72-specific camelid single domain antibodies as targeting agents. <i>Cancer Letters</i> , 2013, 334, 237-244.	3.2	64
107	Combined Fluorimetric Caspase 3/7 Assay and Bradford Protein Determination for Assessment of Polycation-Mediated Cytotoxicity. <i>Methods in Molecular Biology</i> , 2013, 948, 23-33.	0.4	1
108	The Possible –Proton Sponge –Effect of Polyethylenimine (PEI) Does Not Include Change in Lysosomal pH. <i>Molecular Therapy</i> , 2013, 21, 149-157.	3.7	593

#	ARTICLE	IF	CITATIONS
109	Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene. <i>Oncotarget</i> , 2013, 4, 584-599.	0.8	166
110	Heavy Chain Only Antibodies: A New Paradigm in Personalized HER2+ Breast Cancer Therapy. <i>BiolImpacts</i> , 2013, 3, 1-4.	0.7	23
111	Total Internal Reflection Fluorescence (TIRF) Microscopy for Real-Time Imaging of Nanoparticle-Cell Plasma Membrane Interaction. , 2012, 906, 473-482.		10
112	Complement Sensing of Nanoparticles and Nanomedicines. <i>ACS Symposium Series</i> , 2012, , 365-382.	0.5	11
113	Nanotechnology: from fundamental concepts to clinical applications for healthy aging. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2012, 8, S1-S4.	1.7	8
114	Particulate Systems for Targeting of Macrophages: Basic and Therapeutic Concepts. <i>Journal of Innate Immunity</i> , 2012, 4, 509-528.	1.8	66
115	Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2012, 8, S5-S20.	1.7	76
116	PEGylated Nanoparticles Bind to and Alter Amyloid-Beta Peptide Conformation: Toward Engineering of Functional Nanomedicines for Alzheimer's Disease. <i>ACS Nano</i> , 2012, 6, 5897-5908.	7.3	164
117	Polyethylenimine-mediated impairment of mitochondrial membrane potential, respiration and membrane integrity: Implications for nucleic acid delivery and gene therapy. <i>Mitochondrion</i> , 2012, 12, 162-168.	1.6	46
118	Perspectives on carbon nanotube-mediated adverse immune effects. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 1700-1705.	6.6	51
119	Genomic perspectives in inter-individual adverse responses following nanomedicine administration: The way forward. <i>Advanced Drug Delivery Reviews</i> , 2012, 64, 1385-1393.	6.6	44
120	Nanotechnology: From fundamental concepts to clinical applications for healthy aging. <i>Maturitas</i> , 2012, 73, 1-4.	1.0	4
121	Polymeric particulate technologies for oral drug delivery and targeting: A pathophysiological perspective. <i>Maturitas</i> , 2012, 73, 5-18.	1.0	34
122	Factors Controlling Nanoparticle Pharmacokinetics: An Integrated Analysis and Perspective. <i>Annual Review of Pharmacology and Toxicology</i> , 2012, 52, 481-503.	4.2	477
123	Complement system and the brain: Selected pathologies and avenues toward engineering of neurological nanomedicines. <i>Journal of Controlled Release</i> , 2012, 161, 283-289.	4.8	24
124	Reshaping the Future of Nanopharmaceuticals: <i>Ad ludicium</i> . <i>ACS Nano</i> , 2011, 5, 8454-8458.	7.3	90
125	Transformation of structurally diverse steroidal analogues by the fungus <i>Corynespora cassiicola</i> CBS 161.60 results in generation of 8 β -monohydroxylated metabolites with evidence in favour of 8 β -hydroxylation through inverted binding in the 9 α -hydroxylase. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> . 2011, 1811, 1054-1061.	1.2	12
126	Functionalization with ApoE-derived peptides enhances the interaction with brain capillary endothelial cells of nanoliposomes binding amyloid-beta peptide. <i>Journal of Biotechnology</i> , 2011, 156, 341-346.	1.9	92

#	ARTICLE	IF	CITATIONS
127	Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 521-540.	1.7	240
128	Bionanotechnologies for treatment and diagnosis of Alzheimer's disease. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 515-518.	1.7	17
129	Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells. <i>Journal of Controlled Release</i> , 2011, 156, 85-91.	4.8	62
130	Hyaluronan-coated nanoparticles: The influence of the molecular weight on CD44-hyaluronan interactions and on the immune response. <i>Journal of Controlled Release</i> , 2011, 156, 231-238.	4.8	204
131	Biological targeting and innovative therapeutic interventions with phage-displayed peptides and structured nucleic acids (aptamers). <i>Current Opinion in Biotechnology</i> , 2011, 22, 832-838.	3.3	19
132	Material properties in complement activation. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 1000-1007.	6.6	230
133	Complement monitoring of nanomedicines and implants. <i>Advanced Drug Delivery Reviews</i> , 2011, 63, 963-964.	6.6	5
134	Complement activation cascade triggered by PEG-PL engineered nanomedicines and carbon nanotubes: The challenges ahead. <i>Journal of Controlled Release</i> , 2010, 146, 175-181.	4.8	157
135	Cationic carriers of genetic material and cell death: A mitochondrial tale. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2010, 1797, 1203-1209.	0.5	117
136	Complement monitoring of carbon nanotubes. <i>Nature Nanotechnology</i> , 2010, 5, 382-382.	15.6	26
137	Complement monitoring of carbon nanotubes. <i>Nature Nanotechnology</i> , 2010, 5, 382-383.	15.6	13
138	Polycation cytotoxicity: a delicate matter for nucleic acid therapy—focus on polyethylenimine. <i>Soft Matter</i> , 2010, 6, 4001.	1.2	193
139	Engineering Liposomes and Nanoparticles for Biological Targeting. <i>Advances in Biochemical Engineering/Biotechnology</i> , 2010, 125, 251-280.	0.6	33
140	Distinct Polymer Architecture Mediates Switching of Complement Activation Pathways at the Nanosphere-Serum Interface: Implications for Stealth Nanoparticle Engineering. <i>ACS Nano</i> , 2010, 4, 6629-6638.	7.3	263
141	Hypersensitivity Reactions to Nanomedicines: Causative Factors and Optimization of Design Parameters. , 2010, , 225-237.		2
142	Chapter 3. Nanoparticle Engineering for the Lymphatic System and Lymph Node Targeting. <i>RSC Nanoscience and Nanotechnology</i> , 2010, , 81-97.	0.2	4
143	Tunable 3D and 2D polystyrene nanoparticle assemblies using surface wettability, low volume fraction and surfactant effects. <i>Nanotechnology</i> , 2009, 20, 025604.	1.3	14
144	Complement-mediated tumour growth: Implications for cancer nanotechnology and nanomedicines. <i>Molecular Immunology</i> , 2009, 46, 1571-1572.	1.0	19

#	ARTICLE	IF	CITATIONS
145	Factors Controlling Pharmacokinetics of Intravenously Injected Nanoparticulate Systems. , 2009, , 267-282.		3
146	Liposome triggering of innate immune responses: A perspective on benefits and adverse reactions. Journal of Liposome Research, 2009, 19, 85-90.	1.5	104
147	Complement: Alive and Kicking Nanomedicines. Journal of Biomedical Nanotechnology, 2009, 5, 364-372.	0.5	71
148	<l>A Special Issue on</l> Nano- and Micro-Technologies for Biological Targeting, Tracking, Imaging and Sensing. Journal of Biomedical Nanotechnology, 2009, 5, 611-613.	0.5	1
149	Liposome-Mediated Triggering of Complement Cascade. Journal of Liposome Research, 2008, 18, 195-209.	1.5	72
150	Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. Molecular Immunology, 2008, 45, 3797-3803.	1.0	122
151	Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Molecular Immunology, 2008, 46, 225-232.	1.0	231
152	Enhanced lymph node retention of subcutaneously injected IgG1-PEG2000-liposomes through pentameric IgM antibody-mediated vesicular aggregation. Biochimica Et Biophysica Acta - Biomembranes, 2008, 1778, 51-55.	1.4	24
153	Lymphatic targeting of immuno-PEG-liposomes: Evaluation of antibody-coupling procedures on lymph node macrophage uptake. Journal of Drug Targeting, 2008, 16, 586-590.	2.1	13
154	Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug. Expert Opinion on Drug Delivery, 2008, 5, 205-219.	2.4	34
155	Polymeric Nanocarriers for siRNA Delivery: Challenges and Future Prospects. Journal of Biomedical Nanotechnology, 2008, 4, 258-275.	0.5	27
156	Particulate nanomedicine in the footsteps of platelet homing. Nanomedicine, 2007, 2, 381-384.	1.7	1
157	Ordering of Binary Polymeric Nanoparticles on Hydrophobic Surfaces Assembled from Low Volume Fraction Dispersions. Journal of the American Chemical Society, 2007, 129, 13390-13391.	6.6	36
158	Modification of the Stewart biphasic colorimetric assay for stable and accurate quantitative determination of Pluronic and Tetronic block copolymers for application in biological systems. Analytical Biochemistry, 2007, 361, 287-293.	1.1	21
159	Methylation of the phosphate oxygen moiety of phospholipid–methoxy(polyethylene glycol) conjugate prevents PEGylated liposome–mediated complement activation and anaphylatoxin production. FASEB Journal, 2006, 20, 2591-2593.	0.2	185
160	Concentration Dependent Structural Ordering of Poloxamine 908 on Polystyrene Nanoparticles and Their Modulatory Role on Complement Consumption. Journal of Nanoscience and Nanotechnology, 2006, 6, 3126-3133.	0.9	58
161	The effect of methoxy-PEG chain length and molecular architecture on lymph node targeting of immuno-PEG liposomes. Biomaterials, 2006, 27, 136-144.	5.7	73
162	Activation of the Human Complement System by Cholesterol-Rich and PEGylated Liposomes–Modulation of Cholesterol-Rich Liposome-Mediated Complement Activation by Elevated Serum LDL and HDL Levels. Journal of Liposome Research, 2006, 16, 167-174.	1.5	61

#	ARTICLE	IF	CITATIONS
163	Particulate nanomedicines†. <i>Advanced Drug Delivery Reviews</i> , 2006, 58, 1451-1455.	6.6	43
164	Recent Developments in Polymeric Nanoparticle Engineering and Their Applications in Experimental and Clinical Oncology. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2006, 6, 553-561.	0.9	65
165	Polymeric Nanoparticles as Drug Carriers and Controlled Release Implant Devices. , 2006, , 29-42.		9
166	A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy. <i>Molecular Therapy</i> , 2005, 11, 990-995.	3.7	967
167	Editorial [Hot Topic: Lipid-Based Nanosystems and Complexes in Experimental and Clinical Therapeutics (Guest Editors: A. Agrawal and S.M. Moghimi)]. <i>Current Drug Delivery</i> , 2005, 2, 295-295.	0.8	8
168	Low and high molecular weight poly(L-lysine)s/poly(L-lysine)-DNA complexes initiate mitochondrial-mediated apoptosis differently. <i>FEBS Letters</i> , 2005, 579, 6191-6198.	1.3	109
169	Nanomedicine: current status and future prospects. <i>FASEB Journal</i> , 2005, 19, 311-330.	0.2	1,732
170	Cellular Distribution of Nonionic Micelles. <i>Science</i> , 2004, 303, 626-628.	6.0	57
171	Causative factors behind poloxamer 188 (Pluronic F68, Floco [®] , _c)-induced complement activation in human sera. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2004, 1689, 103-113.	1.8	106
172	Synthetic polymers in 21st century therapeutics: the way forward ¾. <i>Drug Discovery Today</i> , 2003, 8, 154-156.	3.2	5
173	Modulation of lymphatic distribution of subcutaneously injected poloxamer 407-coated nanospheres: the effect of the ethylene oxide chain configuration. <i>FEBS Letters</i> , 2003, 540, 241-244.	1.3	61
174	Real-time evidence of surface modification at polystyrene lattices by poloxamine 908 in the presence of serum: in vivo conversion of macrophage-prone nanoparticles to stealth entities by poloxamine 908. <i>FEBS Letters</i> , 2003, 547, 177-182.	1.3	33
175	Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. <i>Progress in Lipid Research</i> , 2003, 42, 463-478.	5.3	1,084
176	Nanoparticle-mediated gene delivery to tumour neovasculature. <i>Trends in Molecular Medicine</i> , 2003, 9, 2-4.	3.5	47
177	Exploitation of Macrophage Clearance Functions In Vivo. <i>Handbook of Experimental Pharmacology</i> , 2003, , 41-54.	0.9	4
178	Endothelial Cells as Therapeutic Targets in Cancer: New Biology and Novel Delivery Systems. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2003, 20, 139-152.	1.2	14
179	LIPOSOME RECOGNITION BY RESIDENT AND NEWLY RECRUITED MURINE LIVER MACROPHAGES. <i>Journal of Liposome Research</i> , 2002, 12, 67-70.	1.5	9
180	PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. <i>FEBS Letters</i> , 2002, 532, 338-344.	1.3	131

#	ARTICLE	IF	CITATIONS
181	Chemical camouflage of nanospheres with a poorly reactive surface: towards development of stealth and target-specific nanocarriers. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2002, 1590, 131-139.	1.9	88
182	Modulation of murine liver macrophage clearance of liposomes by diethylstilbestrol. The effect of vesicle surface charge and a role for the complement receptor Mac-1 (CD11b/CD18) of newly recruited macrophages in liposome recognition. <i>Journal of Controlled Release</i> , 2002, 78, 55-65.	4.8	32
183	Therapeutic synthetic polymers: a game of Russian roulette?. <i>Drug Discovery Today</i> , 2002, 7, 998-1001.	3.2	80
184	Recognition and clearance of methoxypoly(ethyleneglycol)2000-grafted liposomes by macrophages with enhanced phagocytic capacity Implications in experimental and clinical oncology. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2001, 1526, 227-229.	1.1	26
185	Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. , 2001, 18, 1-8.		133
186	Capture of Stealth Nanoparticles by the Body's Defences. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2001, 18, 24.	1.2	125
187	Long-circulating and target-specific nanoparticles: theory to practice. <i>Pharmacological Reviews</i> , 2001, 53, 283-318.	7.1	2,472
188	Capture of stealth nanoparticles by the body's defences. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2001, 18, 527-50.	1.2	37
189	Recent advances in cellular, sub-cellular and molecular targeting. <i>Advanced Drug Delivery Reviews</i> , 2000, 41, 129-133.	6.6	37
190	Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. <i>Trends in Biotechnology</i> , 2000, 18, 412-420.	4.9	351
191	Hormonal Control of Macrophage Phagocytosis of Phospholipid Vesicles. <i>Journal of Liposome Research</i> , 2000, 10, 409-417.	1.5	1
192	Subcutaneous and intravenous delivery of diagnostic agents to the lymphatic system: applications in lymphoscintigraphy and indirect lymphography. <i>Advanced Drug Delivery Reviews</i> , 1999, 37, 295-312.	6.6	129
193	Re-establishing the long circulatory behaviour of poloxamine-coated particles after repeated intravenous administration: applications in cancer drug delivery and imaging. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1999, 1472, 399-403.	1.1	26
194	Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system – The concept of tissue specificity. <i>Advanced Drug Delivery Reviews</i> , 1998, 32, 45-60.	6.6	219
195	Recent Developments and Limitations of Poloxamine-Coated Long-Circulating Particles in Experimental Drug Delivery. , 1998, , 263-274.		0
196	A Single Dose of Intravenously Injected Poloxamine-Coated Long-Circulating Particles Triggers Macrophage Clearance of Subsequent Doses in Rats. <i>Clinical Science</i> , 1997, 93, 371-379.	1.8	54
197	Prolonging the circulation time and modifying the body distribution of intravenously injected polystyrene nanospheres by prior intravenous administration of poloxamine-908. A 'hepatic-blockade' event or manipulation of nanosphere surface in vivo?. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1997, 1336, 1-6.	1.1	37
198	Activation of the mononuclear phagocyte system by poloxamine 908: its implications for targeted drug delivery. <i>Pharmaceutical Research</i> , 1997, 14, 1629-1633.	1.7	4

#	ARTICLE	IF	CITATIONS
199	Altered tissue-specific opsonic activities and opsono-recognition of liposomes in tumour-bearing rats. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1996, 1285, 56-64.	1.4	12
200	Advanced colloid-based systems for efficient delivery of drugs and diagnostic agents to the lymphatic tissues. <i>Progress in Biophysics and Molecular Biology</i> , 1996, 65, 221-249.	1.4	58
201	Poloxamer-188 Revisited: a Potentially Valuable Immune Modulator?. <i>Journal of the National Cancer Institute</i> , 1996, 88, 766-768.	3.0	39
202	Mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers. <i>Advanced Drug Delivery Reviews</i> , 1995, 16, 183-193.	6.6	71
203	Exploiting bone marrow microvascular structure for drug delivery and future therapies. <i>Advanced Drug Delivery Reviews</i> , 1995, 17, 61-73.	6.6	84
204	Mechanisms of splenic clearance of blood cells and particles: towards development of new splenotropic agents. <i>Advanced Drug Delivery Reviews</i> , 1995, 17, 103-115.	6.6	126
205	Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. <i>FEBS Letters</i> , 1994, 344, 25-30.	1.3	129
206	Organ-Specific Targeting of Synthetic and Natural Drug Carriers. <i>Advances in Molecular and Cell Biology</i> , 1994, 9, 263-282.	0.1	4
207	Innovations in avoiding particle clearance from blood by Kupffer cells: cause for reflection. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 1994, 11, 31-59.	1.2	33
208	Microspheres for targeting drugs to specific body sites. <i>Journal of Controlled Release</i> , 1993, 24, 157-163.	4.8	83
209	Current progress and future prospects of liposomes in dermal drug delivery. <i>Journal of Microencapsulation</i> , 1993, 10, 155-162.	1.2	19
210	An investigation of the filtration capacity and the fate of large filtered sterically-stabilized microspheres in rat spleen. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1993, 1157, 233-240.	1.1	151
211	Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1993, 1179, 157-165.	1.9	227
212	Effect of Splenic Congestion Associated with Haemolytic Anaemia on Filtration of α -Spleen-Homing β ™ Microspheres. <i>Clinical Science</i> , 1993, 84, 605-609.	1.8	16
213	Serum factors that regulate phagocytosis of liposomes by Kupffer cells. <i>Biochemical Society Transactions</i> , 1993, 21, 128S-128S.	1.6	25
214	Enhanced hepatic clearance of intravenously administered sterically stabilized microspheres in zymosan-stimulated rats. <i>Journal of Leukocyte Biology</i> , 1993, 54, 513-517.	1.5	50
215	Opsonophagocytosis of liposomes by peritoneal macrophages and bone marrow reticuloendothelial cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1992, 1135, 269-274.	1.9	57
216	The polyoxyethylene/polyoxypropylene block co-polymer Poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. <i>FEBS Letters</i> , 1992, 305, 62-66.	1.3	155

#	ARTICLE	IF	CITATIONS
217	Differences in the molecular weight profile of poloxamer 407 affect its ability to redirect intravenously administered colloids to the bone marrow. <i>International Journal of Pharmaceutics</i> , 1992, 83, 273-276.	2.6	22
218	Non-phagocytic uptake of intravenously injected microspheres in rat spleen: Influence of particle size and hydrophilic coating. <i>Biochemical and Biophysical Research Communications</i> , 1991, 177, 861-866.	1.0	279
219	The effect of block co-polymers on the uptake of model polystyrene microspheres by Kupffer cells - in vitro and in vivo studies. <i>Biochemical Society Transactions</i> , 1991, 19, 329S-329S.	1.6	19
220	The effect of poloxamer-407 on liposome stability and targeting to bone marrow: comparison with polystyrene microspheres. <i>International Journal of Pharmaceutics</i> , 1991, 68, 121-126.	2.6	57
221	Calcium as a possible modulator of Kupffer cell phagocytic function by regulating liver-specific opsonic activity. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1990, 1028, 304-308.	1.4	18
222	Tissue Specific Serum Opsonins and Phagocytosis of Liposomes. , 1990, , 87-94.		4
223	Physiopathological and physicochemical considerations in targeting of colloids and drug carriers to the bone marrow. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 1990, 7, 187-209.	1.2	6
224	Differential properties of organ-specific serum opsonins for liver and spleen macrophages. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1989, 984, 379-383.	1.4	82
225	Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1989, 984, 384-387.	1.4	110
226	Tissue specific opsonins for phagocytic cells and their different affinity for cholesterol-rich liposomes. <i>FEBS Letters</i> , 1988, 233, 143-147.	1.3	138
227	The Innate Immune Responses, Adjuvants and Delivery Systems. , 0, , 113-127.		5
228	The Role of Complement in Antibody Therapy for Infectious Diseases. , 0, , 63-74.		0